Premium
Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas
Author(s) -
Sordillo Peter P.,
Magill Gordon B.,
Brenner Joseph,
Cheng Edgar W.,
Dosik Michael,
Yagoda Alan
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870301)59:5<884::aid-cncr2820590504>3.0.co;2-k
Subject(s) - medicine , nausea , vomiting , soft tissue sarcoma , cisplatin , soft tissue , diuresis , creatinine , phases of clinical research , chemotherapy , urology , surgery , renal function
A Phase II trial of moderately high‐dose cisplatin (120 mg/m 2 with mannitol diuresis) was conducted in 26 previously untreated patients with soft tissue sarcomas. One partial response (major response rate, 4%) and two minor responses were seen. Severe nausea and vomiting and transient increases in the serum creatinine level were the most common side effects of treatment. Cisplatin has minimal activity as a single agent in patients with soft tissue sarcoma. Cancer 59:884‐886, 1987.